Next Science (ASX:NXS) share price higher on earnings mixed bag

The Next Science (ASX:NXS) share price is pushing higher today after the company released its full-year earnings. Here are the details!

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Next Science Ltd (ASX: NXS) shares are pushing higher today on the back of the company delivering its full-year results for the 12 months ending 31 December 2020 this morning. The Next Science share price opened lower this morning at $1.21 but at the time of writing, has jumped 3.25% higher to $1.27.

What did the company report?

The Next Science share price is leaping higher this morning after the company released its results covering the 2020 calendar year, thus incorporating the most significant impacts of COVID-19 on its activities. Next Science reported that revenues came in at US$3.44 million, down 15% from 2019's US$4.06 million.

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) fell 3% from 2019's loss of US$11.13 million to a loss of US$11.49 million for 2020. Gross profits were US$2.92 million for 2020, down 17% from 2019's US$3.91 million. Gross margins on sales came in at 85% though, down slightly on 2019's 86%. Overall, expenses fell 2% for 2020 to US$14.4 million, down from 2019's US$14.64 million.

As of 31 December 2020, Next Science reported it had US$15.3 million in net cash. That was assisted by the company's recent capital raise.

Next Science told investors that revenue was held back by the COVID-19 pandemic, which resulted in a "shut down of elective surgeries and [the] closure of wound care clinics". This reportedly hit sales of the company's BlastX product especially hard, given sales were down 75% year on year. That was somewhat offset by lower expenses as a result of reduced travel expenditure and a reduction in staff headcount.

Despite this mixed bag of results, the Next Science share price is pushing higher as the company remains bullish on its future. Next Science highlighted that revenue in the quarter ending 31 December saw revenue growth return and sales that were 75% above the same quarter in 2019. The health care company advised investors that this run rate "is expected to continue in 1H 2021".

What is Next Science?

Next Science is an ASX health care company that specialises in antimicrobial balms and solutions. It is currently the only company worldwide that has products approved to treat biofilm-based infections.

Next Science has three available products in the United States market, as well as regulatory approvals in several European countries, the United Kingdom and Australia. It has another product called XPerience that is set for launch in the first half of this year, pending approval from the US Food and Drug Administration (FDA).

Next Science share price snapshot

Over the past 12 months, the Next Science share price has fallen by nearly 34%. The company's shares have increased 27% since their March 2020 low of $1.00. Based on the current Next Science share price, the company has a market capitalisation of around $150 million.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nexus Energy Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »